Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 08:46:00 2025-01-15 am EST			5-day change	1st Jan Change
20.81 ^EUR	+6.15%		+5.84%	+7.77%

10:32am	Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	MT
09:18am	Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	DP

Bayer: to present its radiology products at RSNA

December 02, 2024 at 06:24 am EST

Bayer continues to advance its comprehensive portfolio of radiology products through advances in the development pipeline and innovations in artificial intelligence (AI).

The company will present new data on gadoquatrane, the low-dose gadolinium-based macrocyclic contrast agent currently in Phase III development, at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held December 1-5 in Chicago, USA.

At the meeting, Bayer also announced progress on a collaboration with global medical technology company Subtle Medical.

"The common goal is to harness the power of AI in medical imaging: The companies have agreed to advance the development of the SubtleGAD experimental deep learning algorithm, with the aim of enabling experimental dose reduction of specific gadolinium-based contrast agents for patients undergoing contrast-enhanced MRI, while maintaining diagnostic efficacy' says the group.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Bayer AG

Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	04:32am	MT
Bayer suffers next PCB defeat in the US – waiting for the highest court in the land	03:18am	DP
After Asundexian setback: Bayer optimistic about new blockbusters	01:23am	RE
Another setback: Bayer ordered to pay damages in PCB trial	12:36am	RE
Bayer Hit with $100 Million Verdict by US Jury Over US School Contamination	12:15am	MT
Bayer Aktiengesellschaft Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 10:30 AM	Jan. 14
Bayer pharma chief sees no big acquisitions in near future	Jan. 14	RE
Bayer: first participants in AskBio trial	Jan. 14	CF
Bayer continues to focus on revitalizing its pharmaceuticals business in the medium term – no major deals	Jan. 14	DP
Bayer will focus on debt reduction rather than acquisitions in the coming years	Jan. 14	RE
German Stocks Retreat Amid US Rate Jitters	Jan. 13	MT
Bayer to Commence Late-stage Study for Parkinson's Disease Therapy	Jan. 13	MT
Bayer: towards a Phase III study in Parkinson's disease	Jan. 13	CF
Bayer is starting a crucial cell therapy study for Parkinson's disease	Jan. 13	RE
Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar	Jan. 13	MT
Farmers see difficult business situation in 2025	Jan. 11	DP
Bayer Announces Positive Topline Results of the Pivotal Phase III Quanti Studies Evaluating the Efficacy and Safety of Gadoquatrane, an Investigational Gadolinium-Based Contrast Agent for Use in Magnetic Resonance Imaging	Jan. 10	CI
Bayer Files Marketing Authorization Applications for New Indication of Finerenone in US, China	Jan. 10	MT
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA®	Jan. 10	CI
Bayer: positive results for an MRI contrast agent	Jan. 10	CF
Bayer's MRI Contrast Agent Meets Primary, Secondary Endpoints in Late-stage Studies	Jan. 10	MT
German Stocks Muted Amid Local Economic Data Focus	Jan. 09	MT
Bayer to Buy Smart Earth Camelina's Oilseed Crop	Jan. 09	MT
Bayer: completes acquisition of Camelina assets	Jan. 09	CF
Bayer: new positive data for elinzanetant	Jan. 09	CF

Chart Bayer AG

Duration

Period

BAYN: Dynamic Chart

Company Profile

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

2025-01-21 - UniCredit Kepler Cheuvreux German Corporate Conference

More about the company